Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer
Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the company as President and Chief Executive Officer (CEO).
- Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the company as President and Chief Executive Officer (CEO).
- “I am delighted to welcome George to the Mythic team,” said Brian Fiske, Ph.D., Chief Scientific Officer and Co-Founder at Mythic Therapeutics.
- Prior to that, Dr. Eliades spent over 20 years at Bain & Company and Monitor Group, advising biotech clients in corporate strategy, M&A, growth and digital-driven transformations.
- Dr. Eliades stated, “I’m incredibly excited to join Mythic and work toward improving outcomes for more cancer patients through our pipeline of innovative ADCs.